Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.87M
Average 0.88M
CLYM EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Climb Bio, Inc.NASDAQ: CLYM
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.2, compared with -$0.31 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.78.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 10 analysts of -$0.87 (+0.9%) for the fiscal year ending Dec 2026, a slowdown from the +42.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.2+23.1% QoQ
- Last fiscal yearDec 2025
- -$0.88+42.5% YoY
- LTMMar 2026
- -$0.78+67.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +35.5% | -65.6% | -101.1 pp |
| 1 year | +42.5% | +0.9% | -41.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.88) USD
- Year-over-year change
- +42.5%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.88) | +42.5% |
| FY2024 | 2024-12-31 | (1.53) | -17.7% |
| FY2023 | 2023-12-31 | (1.30) | +24.4% |
| FY2022 | 2022-12-31 | (1.72) | +59.4% |
| FY2021 | 2021-12-31 | (4.24) | — |
EPS (Diluted) vs competitors
How CLYM compares with its peers on the latest reported figures
- CLYM's LTM Mar 2026 EPS (Diluted) of -$0.78 is the 2nd highest of the 5 companies compared; the peer median is -$1.42.
- Its year-over-year change of +67.2% is the highest of 4, against a peer median of +23.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $0 | — | — |
CLYMClimb Bio, Inc. | LTM Mar 2026 | -$0.78 | +67.2% | — |
| LTM Mar 2026 | -$0.87 | +60.7% | — | |
| LTM Mar 2026 | -$1.97 | +23.0% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | -$2.91 | -70.2% | — |
| Peer median (excluding CLYM) | -$1.42 | +23.0% | — | |
Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 97K |
| Gross Profit | 0 | 0 | 0 | 0 | (97K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.32M | 26.21M | 15.41M | 14.34M | 46.62M |
| Selling, General & Admin | 12.35M | 18.92M | 24.86M | 16.03M | 21.17M |
| Operating Expenses | 35.67M | 45.14M | 40.28M | 82.02M | 67.79M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| EBITDA | (47.48M) | (45.24M) | (35.12M) | (30.36M) | (59.75M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.67M) | (45.14M) | (40.28M) | (82.02M) | (67.88M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.38M | 4.62M | 8.13M | 8.32M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (11.81M) | (109K) | 5.16M | 8.12M | 8.03M |
| Income Before Tax | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| EPS (Diluted) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| Weighted Avg Shares | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
| Weighted Avg Shares (Diluted) | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.